←
Erin Schenk, MD, PhD222 posts
Erin Schenk, MD, PhD avatar

Erin Schenk, MD, PhD

@SchenkLab

Thoracic Med Onc | Scientist @CUAnschutz | My lab studies the interface between the immune system and lung cancer | Immunotherapy enthusiast | @MayoHemeOnc Alum

◷ Joined August 2019▧ 25 Photos and videos
Erin Schenk, MD, PhD avatar
Erin Schenk, MD, PhD@SchenkLab·6 Dec 2024

Thrilled to be part of the Lung TeamLab and the incredible collaboration to eliminate residual disease!

Today we launch the PoweRD 2 Cure ALK+ Lung Cancer TeamLab! Uniting researchers from @DanaFarber @MDAndersonNews @kochinstitute @KimmelCancerCtr @MSKCancerCenter @BostonChildrens @MGHCancerCenter @CUCancerCenter @VUMC_Cancer in radical collaboration to target residual lung cancer cells remaining after initial therapy. Read more: breakthroughcancer.org/2024/…

0:05
Erin Schenk, MD, PhD avatar
Erin Schenk, MD, PhD@SchenkLab·22 May 2024

The promise of immune-based therapies still needs to reach patients with NSCLC bearing driver alterations. We need to look beyond checkpoint inhibitors. Thank you @NarjustFlorezMD and @BiagioRicciutMD for the amazing discussion! #LCSM

I hope you are ready for this discussion with Drs. @SchenkLab & @BiagioRicciutMD I learned SO much only in the first 5 minutes of this conversation about the use of IO in patients with NSCLC and driver mutations. Including -Toxicity -Importance of NGS -Prognostic and predictive markers -The impact of tumor microenvironment Lung Cancer Considered the official @IASLC podcast ⌛️💉🧬🧫🧪

Post attachment
Erin Schenk, MD, PhD avatar
Erin Schenk, MD, PhD@SchenkLab·14 Dec 2023

One of the best parts of this job is seeing your mentees succeed. Keep up the great work Patrick and Amaie (not pictured but proud to say he got into pharmacy school!). Hearing from both made my day

Post attachment
Erin Schenk, MD, PhD avatar
Erin Schenk, MD, PhD@SchenkLab·10 Aug 2023

I often share the words of a mentor/hero of mine (a hematologist) in my clinical practice as a thoracic oncologist: “It is better to start the right treatment rather than the fast one.”

More data showing the importance of *waiting* for NGS results before starting NSCLC therapy whenever possible! Retrospective analysis @JCOOP_ASCO show that when treatment of driver+ NSCLC before biomarker results is associated with inferior survival. ascopubs.org/doi/abs/10.1200…

Post attachment
Erin Schenk, MD, PhD avatar
Erin Schenk, MD, PhD@SchenkLab·30 Jun 2023

Thank you for the invitation to speak! One day would love to be part of a session focused on novel immune approaches for EGFR/ALK/ROS1. Cell therapies, BiTEs, macrophage check points…

Fascinating lecture describing how the interaction between tumor cells and macrophages in the TME can drive resistance to targeted therapies. Looking forward to future work from @SchenkLab in this space! #DAVAHawaiiLung

Post attachmentPost attachment
Erin Schenk, MD, PhD avatar
Erin Schenk, MD, PhD@SchenkLab·21 Apr 2023

Highly recommend! The MBCO AACR course was an incredible opportunity to meet with other physician scientists, discuss opportunities and challenges unique to this path. Thank you @christine_lovly for encouraging me to apply

Tagging some of the many amazing people I have met at the @AACR MBCO course: @DrBetofMDPhD @juanosoriomd @BZhangMD @SchenkLab @josephcmurray @catherine_fahey @cnebhan @jmchan88, @JenWargoMD, @carlhjune. Please spread the word about the course! aacr.org/meeting/molecular-b…

Post attachment